Reslizumab: Effectiveness one month after first dose.

I. Lobato Astiarraga (Ávila, Spain), M. López Zubizarreta (Ávila, Spain), A. Andrés Porras (Ávila, Spain), J. Marcos Sierra (Ávila, Spain), J. Tenes Mayen (Ávila, Spain), R. Pajares Mediavilla (Ávila, Spain), J. Tapias Del Pozo (Ávila, Spain), J. Hernández Hernández (Ávila, Spain)

Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Session: Clinical and laboratory pharmacology in asthma
Session type: E-poster session
Number: 1407
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Lobato Astiarraga (Ávila, Spain), M. López Zubizarreta (Ávila, Spain), A. Andrés Porras (Ávila, Spain), J. Marcos Sierra (Ávila, Spain), J. Tenes Mayen (Ávila, Spain), R. Pajares Mediavilla (Ávila, Spain), J. Tapias Del Pozo (Ávila, Spain), J. Hernández Hernández (Ávila, Spain). Reslizumab: Effectiveness one month after first dose.. 1407

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 302s
Year: 2002

Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period
Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up
Year: 2007


Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients
Source: Eur Respir J 2002; 20: Suppl. 38, 525s
Year: 2002

Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006

Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study
Source: Eur Respir J 2006; 28: Suppl. 50, 207s
Year: 2006

Six month treatment with formoterol - efficacy and side effects
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up
Source: Eur Respir J 2005; 26: Suppl. 49, 369s
Year: 2005

Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE)
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005

Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study)
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006

Quality of life of stable dose treatment with salmeterol/fluticasone (SFC) compared with adjustable maintenance dosing (AMD) with formoterol/budesonide (FBC)
Source: Eur Respir J 2005; 26: Suppl. 49, 252s
Year: 2005

Cost effectiveness of inpatient initiated varenicline tartrate (VT) plus counselling compared to counselling alone: 2 year follow-up of the Smoking Termination Opportunity for inPatients (STOP) study
Source: International Congress 2016 – Emerging issues in smoking cessation and tobacco products
Year: 2016


Late Breaking Abstract - Short 12-month regimen with intravenous linezolid for pre-XDR TB: treatment outcomes and 24 months follow-up results
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019

RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults
Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term
Year: 2021


LATE-BREAKING ABSTRACT: Effectiveness of training session on the inhalation technique of the BA-pMDI Autohaler® (containing beclometasone) in daily practice.
Source: Annual Congress 2013 –Improving educational programmes for patients and multidisciplinary healthcare professionals
Year: 2013


Effectiveness evaluation of anti-IgE treatment at 3rd year: Real life Turkey data
Source: International Congress 2016 – Asthma points to ponder
Year: 2016


Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011

Efficacy, safety and tolerability of 3 day azithromycin versus 10-day amoxillin/clavulanic acid in the treatment of children with pneumonia
Source: Eur Respir J 2003; 22: Suppl. 45, 143s
Year: 2003